Mobility Management

  • Home
  • Topics
    • Automotive Mobility
    • Billing / Reimbursement
    • Government / Legislation
    • Home Accessibility
    • Pediatrics
    • Power Chairs
    • Seating & Positioning
    • Ultralightweights
  • News
  • Featured
  • Podcasts
  • Request Media Kit
  • Webinars
  • Subscribe
  • Digital Edition
  • Awards
  • Advertise

Studies: Psoriasis Medication Effective as MS Treatment

October 1, 2012 by Laurie Watanabe

Dimethyl fumarate, also known as BG-12, has been found to be an effective treatment for multiple sclerosis (MS) according to a pair of studies recently published by the New England Journal of Medicine.

The chemical has been commonly used to prevent mold in consumer products such as leather goods and furniture, and that use for dimethyl fumarate was banned in the European Union (EU) several years ago because of consumer complaints of itching, rashes and other allergic reactions, according to EUROPA, the EU’s official Web site. Germany approved BG-12 as a psoriasis treatment in the 1990s.

Now, the Journal reports that trial participants who took BG-12 orally two or three times daily showed reduced numbers of MS relapses and brain lesions compared to those participants who had been on the placebo. The participants had been diagnosed with relapsing-remitting MS.

Patients receiving the doses of BG-12 also experienced a slowing of disease progression.

A Journal article about the studies said BG-12 “was shown to have anti-inflammatory and cytoprotective (i.e., cell-protective) properties in preclinical experiments and to result in significant reductions in disease activity on magnetic resonance imaging (MRI) in a phase 2, placebo-controlled study involving patients with relapsing-remitting multiple sclerosis.”

Participants who received the BG-12 doses received 240 mg per dose. “The primary end point was the proportion of patients who had a relapse by two years,” the article said. “Other end points included the annualized relapse rate, the time to confirmed progression of disability, and findings on MRI.”

Of patients who received the BG-12 doses twice daily, 27 percent experienced MS relapses; 26 percent of patients who received three doses per day relapsed. The placebo group relapsed at a rate of 46 percent.

Reported side effects of the BG-12 included gastrointestinal issues such as nausea and upper abdominal pain, as well as decreased lymphocyte (a type of white blood cell) counts and elevated liver aminotransferase (i.e., enzyme) levels, the Journal article said. Elevated liver aminotransferase levels can be an indication of liver inflammation or damage, according to MayoClinic.com.

Related Articles Read More >

RESNA Seeks Donations for New Denis K. Anson Innovation Award
An endowment will support an award given to the Audience Favorite winner of the annual Developers Showcase.
Accessibility Advocates: WestJet Power Wheelchair Weight Limit Excludes CRT Consumers
The Canadian-based airline has a 300-lb. weight limit for power chairs it transports.
Shepherd Center Webinar to Demonstrate WC-FIT Assessment Tool
The Feb. 17 presentation is free to attend.
Capitol dome against blue sky with white clouds
Ultralightweight Upgrade Bill Called ‘Common Sense’ at Congressional Meeting
H.R. 1703 would reduce the financial barriers for Medicare beneficiaries.

GET THE FREE NEWSLETTER

Mobility Management Newsletter

Subscribe to Mobility Management's newsletter for industry & product news, trends and resources. Click here.
podcasts
Mobility Management
  • HME Business
  • Senior Housing News
  • Home Health Care News
  • Skilled Nursing News
  • Hospice News
  • Behavioral Health Business
  • Contact Us
  • About Us

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Mobility Management

  • Home
  • Topics
    • Automotive Mobility
    • Billing / Reimbursement
    • Government / Legislation
    • Home Accessibility
    • Pediatrics
    • Power Chairs
    • Seating & Positioning
    • Ultralightweights
  • News
  • Featured
  • Podcasts
  • Request Media Kit
  • Webinars
  • Subscribe
  • Digital Edition
  • Awards
  • Advertise